Idorsia Ltd
IDIA
Company Profile
Business description
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
Contact
Hegenheimermattweg 91
Allschwil4123
CHET: +41 588441010
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
552
Stocks News & Analysis
stocks
3 global ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies? Our analysts think so.
stocks
What next for Nine Entertainment after Domain payout?
The media group has excelled in controlling what it can control. Now the focus shifts to capital deployment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,128.70 | 18.10 | 0.20% |
| CAC 40 | 7,825.24 | 1.72 | 0.02% |
| DAX 40 | 23,698.15 | 5.50 | -0.02% |
| Dow JONES (US) | 45,834.22 | 273.78 | -0.59% |
| FTSE 100 | 9,283.29 | 14.29 | -0.15% |
| HKSE | 26,388.16 | 301.84 | 1.16% |
| NASDAQ | 22,141.10 | 98.03 | 0.44% |
| Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
| NZX 50 Index | 13,227.90 | 1.25 | -0.01% |
| S&P 500 | 6,584.29 | 3.18 | -0.05% |
| S&P/ASX 200 | 8,864.90 | 22.00 | 0.25% |
| SSE Composite Index | 3,870.60 | 4.71 | -0.12% |